Novartis (NOVN SW) reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia versus placebo in adults with IgA nephropathy
#SWITZERLAND#UNITED KINGDOM#EUROPE#NOVARTIS AG#3I GROUP PLC#EQUITIES#EU SESSION#PHARMACEUTICALS#ASSET MANAGEMENT & CUSTODY BANKS#PHARMACEUTICALS (GROUP)#CAPITAL MARKETS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#FINANCIAL SERVICES#SWISS MARKET INDEX#FTSE 100 INDEX#NOVN#III#SMI